This Week’s Life Science Headlines

January 23, 2014
/
Class Action Design Defect FDA Litigation Medical Device News Nutritional Supplements Pharmaceuticals Preemption Product Liability Recalls Regulatory Supplements
/

Life Science Matters

Litigation

Pharma Can Be Liable for Design Negligence: Pa. High Court (subscription required)
Pfizer Escapes Whistleblower Suit Over Lipitor Marketing (subscription required)
23andMe Faces Suit Over Recently Banned DNA Tests (subscription required)
Claims and Classes in Medical Monitoring Cases (subscription required)
Boston Scientific Mesh Lawsuit to Move Forward After SOL Challenge
Motion Filed to Centralize OxyElite Pro Lawsuits in MDL
6^th Circuit Revives Mylan Wrongful Death Suit (subscription required)
Jury Clears Abbott In Tainted Formula Injury Suit (subscription required)
Ethicon

New Jersey Supreme Court Rejects Federal Approach, Refuses to Consolidate Tylenol Liver Cases in New Jersey

August 29, 2013
/
Pharmaceuticals
/

Life Science Matters

On August 16, 2013 the New Jersey Supreme Court denied a request to consolidate all pending Tylenol liver injury lawsuits in the state court system before a single judge, finding that the cases were inappropriate for centralized management as “Multicounty Litigation”. Earlier this year, the U.S. Judicial Panel on Multidistrict Litigation established coordinated proceedings for Tylenol litigation, assigning Judge Lawrence Stengel of the United States District Court, Eastern District of Pennsylvania, to supervise all pretrial proceedings. Approximately 14 lawsuits have been filed in New Jersey…
Continue reading...

Centralized Status Rejected for Tylenol Liver-Injury Suits

H. Lockwood Miller III

The New Jersey Supreme Court has rejected yet another application — again by a defendant — for centralization under Rule 4:38A. As we previously noted, Johnson & Johnson earlier this year submitted an application seeking centralization of all suits alleging liver damage from the ingestion of Tylenol in Middlesex County. J&J’s application came on the heels of the establishment of a federal MDL on the same issue. In a notice dated last month and released last week, the NJ Supreme Court rejected J&J’s request. …
Continue reading...

Tylenol Subject of Latest New Jersey Centralized Management Request

H. Lockwood Miller III

Suits alleging liver damage from acetaminophen are the latest subject of a request for centralized management in New Jersey. Late last month, McNeil-PPC and Johnson & Johnson submitted an application seeking centralized management of all pending New Jersey lawsuits involving alleged liver damage from Tylenol products. The application, which comes on the heels of the establishment of a federal Multi-District Litigation for similar suits pending in the federal courts, seeks centralization of all New Jersey Tylenol cases in Middlesex County before Judge Mayer, rather than…
Continue reading...

Life Science Matters An inside look at the latest legal developments involving medical devices, pharmaceuticals, and more

This Week’s Life Science Headlines

New Jersey Supreme Court Rejects Federal Approach, Refuses to Consolidate Tylenol Liver Cases in New Jersey

Centralized Status Rejected for Tylenol Liver-Injury Suits

Tylenol Subject of Latest New Jersey Centralized Management Request

Multicounty Litigation Order in New Jersey Provides No Guidance to Practitioners June 23, 2021

New Multicounty Litigation Application in New Jersey June 8, 2021

Lack of Agreement to Arbitrate Dooms Bid to Compel Arbitration May 26, 2021

Mixed Bag in New Jersey Medical Device Preemption Opinion May 12, 2021

First Circuit Agrees Pharmacists Provide Services, Not Sell Goods April 27, 2021